{"id":680,"date":"2019-05-29T12:03:00","date_gmt":"2019-05-29T12:03:00","guid":{"rendered":"https:\/\/preprod.treefrog.fr\/?p=680"},"modified":"2021-04-08T12:04:55","modified_gmt":"2021-04-08T12:04:55","slug":"treefrogs-ceo-cto-cited-in-labiotech-eu","status":"publish","type":"post","link":"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/","title":{"rendered":"TreeFrog&#8217;s CEO\/CTO cited in Labiotech.eu"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"680\" class=\"elementor elementor-680\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2fc4bd0 elementor-section-boxed elementor-section-height-default elementor-section-height-default parallax_section_no qode_elementor_container_no\" data-id=\"2fc4bd0\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-76173f2\" data-id=\"76173f2\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-aea965e elementor-widget elementor-widget-text-editor\" data-id=\"aea965e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"color: rgb(61, 45, 45); font-size: 18px; background-color: rgb(255, 255, 255);\">Kevin Alessandri, CEO\/CTO of TreeFrog was cited in a recent article of Labiotech.eu on the current obstacles preventing cell therapies to become mainstream.&nbsp;<\/span><a href=\"http:\/\/treefrog-obstacles-stopping-cell-therapy-becoming-mainstream\/\" style=\"background-color: rgb(255, 255, 255); text-decoration-line: underline; font-size: 18px;\">Read more<\/a><br><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Kevin Alessandri, CEO\/CTO of TreeFrog was cited in a recent article of Labiotech.eu on the current obstacles preventing cell therapies to become mainstream.&nbsp;Read more<\/p>\n","protected":false},"author":1,"featured_media":683,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[12,13],"tags":[],"aioseo_notices":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TreeFrog&#039;s CEO\/CTO cited in Labiotech.eu - TreeFrog Therapeutics I iPS-derived cell therapies<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TreeFrog&#039;s CEO\/CTO cited in Labiotech.eu - TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"og:description\" content=\"Kevin Alessandri, CEO\/CTO of TreeFrog was cited in a recent article of Labiotech.eu on the current obstacles preventing cell therapies to become mainstream.&nbsp;Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/\" \/>\n<meta property=\"og:site_name\" content=\"TreeFrog Therapeutics I iPS-derived cell therapies\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-29T12:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-08T12:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2021\/04\/treefrog-obstacles-stopping-cell-therapy-becoming-mainstream.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Piergueritona\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/\",\"url\":\"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/\",\"name\":\"TreeFrog's CEO\/CTO cited in Labiotech.eu - TreeFrog Therapeutics I iPS-derived cell therapies\",\"isPartOf\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\"},\"datePublished\":\"2019-05-29T12:03:00+00:00\",\"dateModified\":\"2021-04-08T12:04:55+00:00\",\"author\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\"},\"breadcrumb\":{\"@id\":\"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/preprod.treefrog.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TreeFrog&#8217;s CEO\/CTO cited in Labiotech.eu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#website\",\"url\":\"https:\/\/preprod.treefrog.fr\/\",\"name\":\"TreeFrog Therapeutics I iPS-derived cell therapies\",\"description\":\"Cell Therapy for All\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/preprod.treefrog.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220\",\"name\":\"Piergueritona\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g\",\"caption\":\"Piergueritona\"},\"sameAs\":[\"https:\/\/preprod.treefrog.fr\"],\"url\":\"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TreeFrog's CEO\/CTO cited in Labiotech.eu - TreeFrog Therapeutics I iPS-derived cell therapies","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"TreeFrog's CEO\/CTO cited in Labiotech.eu - TreeFrog Therapeutics I iPS-derived cell therapies","og_description":"Kevin Alessandri, CEO\/CTO of TreeFrog was cited in a recent article of Labiotech.eu on the current obstacles preventing cell therapies to become mainstream.&nbsp;Read more","og_url":"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/","og_site_name":"TreeFrog Therapeutics I iPS-derived cell therapies","article_published_time":"2019-05-29T12:03:00+00:00","article_modified_time":"2021-04-08T12:04:55+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/preprod.treefrog.fr\/wp-content\/uploads\/2021\/04\/treefrog-obstacles-stopping-cell-therapy-becoming-mainstream.jpeg","type":"image\/jpeg"}],"author":"Piergueritona","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/","url":"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/","name":"TreeFrog's CEO\/CTO cited in Labiotech.eu - TreeFrog Therapeutics I iPS-derived cell therapies","isPartOf":{"@id":"https:\/\/preprod.treefrog.fr\/#website"},"datePublished":"2019-05-29T12:03:00+00:00","dateModified":"2021-04-08T12:04:55+00:00","author":{"@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220"},"breadcrumb":{"@id":"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/preprod.treefrog.fr\/treefrogs-ceo-cto-cited-in-labiotech-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/preprod.treefrog.fr\/"},{"@type":"ListItem","position":2,"name":"TreeFrog&#8217;s CEO\/CTO cited in Labiotech.eu"}]},{"@type":"WebSite","@id":"https:\/\/preprod.treefrog.fr\/#website","url":"https:\/\/preprod.treefrog.fr\/","name":"TreeFrog Therapeutics I iPS-derived cell therapies","description":"Cell Therapy for All","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/preprod.treefrog.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/ab868aec652cf07c221b48c1dc91a220","name":"Piergueritona","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/preprod.treefrog.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5270054e7ba7a649b1bc59c924e224e1?s=96&d=mm&r=g","caption":"Piergueritona"},"sameAs":["https:\/\/preprod.treefrog.fr"],"url":"https:\/\/preprod.treefrog.fr\/author\/piergueritona\/"}]}},"_links":{"self":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/680"}],"collection":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/comments?post=680"}],"version-history":[{"count":0,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/posts\/680\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media\/683"}],"wp:attachment":[{"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/media?parent=680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/categories?post=680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/preprod.treefrog.fr\/wp-json\/wp\/v2\/tags?post=680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}